Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 16, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how certain markers in the skin and blood can predict how well patients with chronic inflammatory skin diseases respond to different treatments. Conditions being studied include atopic dermatitis, psoriasis, and several others, which can affect not just the skin but also other parts of the body like joints and muscles. By identifying these markers, researchers hope to improve how treatments are chosen and tailored for each individual, ultimately leading to better outcomes and the development of new treatments.

To participate in the trial, individuals must be at least 18 years old and have a diagnosis of moderate to severe chronic inflammatory skin disease. Healthy volunteers who have had plastic surgery and have no skin or systemic inflammatory diseases are also welcome. Participants will provide informed consent and may undergo tests to help identify these important markers. The trial is not yet recruiting, so interested individuals can keep an eye out for updates on how to get involved.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients:
• • Age\>18 years
• • Informed consent signed by the patient
• • Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis
• • Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification \[1\], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction).
• Healthy controls :
• • Age\>18 years
• • Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants
• • Informed consent signed by the patient
• • Absence of known cutaneous or systemic inflammatory disease.
• Exclusion Criteria:
• • Under guardianship or curatorship
• • Pregnant or breastfeeding woman
• • Lack of affiliation with a social security system
• • Systemic treatment in progress or received less than 3 months ago.